Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patientsGianmaria Baldin, Simona Di Giambenedetto, Arturo Ciccullo et al.|International Journal of Antimicrobial Agents|2019Cited by 55
Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical TrialStefano Rusconi, Giulia Marchetti, Emanuele Focà et al.|PLoS ONE|2013Cited by 42
A Comparison between two Dolutegravir-Based two-drug Regimens as Switch Strategies in a Multicentre Cohort of HIV-1-Infected PatientsArturo Ciccullo, Simona Di Giambenedetto, Gianmaria Baldin et al.|Antiviral Therapy|2018Cited by 37
Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive FindingArturo Ciccullo, Gianmaria Baldin, Vanni Borghi et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2021Cited by 34
Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort studyBarbara Rossetti, Giordano Madeddu, Gianmaria Baldin et al.|Antiviral Research|2019Cited by 32